Johnson & Johnson says COVID-19 vaccine protects against delta variant

Live Science | Jul 2, 2021 at 7:44 PM
  • The Johnson & Johnson COVID-19 vaccine is highly effective against the highly transmissible delta variant, the company announced on Thursday (July 1).
  • The first, based on data from eight participants in the company’s phase 3 trial, found that the vaccine generated neutralizing antibodies — immune system cells that bind to the virus and inactivate it before it can infect cells — against the delta variant.
  • The level of neutralizing antibodies increased with time: People had a higher average number of neutralizing antibodies eight months after they were vaccinated compared with 29 days after they were vaccinated.